[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"doc-seo-367602-105":3,"detail-sidebar-cat-0-en-105":81,"doc-detail-367602-en":130},{"code":4,"msg":5,"data":6},0,"ok",{"site_id":7,"language":8,"slug":9,"title":10,"keywords":11,"description":12,"schema_data":13,"social_meta":74,"head_meta":76,"extra_data":78,"updated_unix":80},105,"en","loss-of-lats1-and-lats2-promotes-ovarian-tumor-formation-by-enhancing-akt-activity-and-pd-l1-expression","Loss of LATS1 and LATS2 promotes ovarian tumor formation by enhancing AKT activity and PD-L1 expression","","High-grade serous ovarian cancer (HGSOC) is highly lethal and commonly becomes resistant to standard platinum chemotherapy. Large tumor suppressors LATS1 and LATS2, core Hippo signaling kinases, are frequently reduced or lost in these cancers. This study shows that LATS1/2 inactivation can transform normal mouse ovarian epithelium into tumorigenic cells with increased proliferation, invasion, stemness, and EMT features. Lats1/2 loss elevates PD-L1 and increases PI3K-AKT activity, while the effects are partially reversed by the AKT inhibitor MK2206 and reduced by the YAP/TAZ inhibitor verteporfin. The work identifies LATS1/2 as potential prognostic markers and therapeutic targets.",{"@graph":14,"@context":73},[15,34,56],{"@type":16,"itemListElement":17},"BreadcrumbList",[18,23,27,31],{"item":19,"name":20,"@type":21,"position":22},"https://docshare.wps.com","Home","ListItem",1,{"item":24,"name":25,"@type":21,"position":26},"https://docshare.wps.com/document/","Document",2,{"item":28,"name":29,"@type":21,"position":30},"https://docshare.wps.com/document/research-report/","Research & Report",3,{"item":32,"name":10,"@type":21,"position":33},"https://docshare.wps.com/document/loss-of-lats1-and-lats2-promotes-ovarian-tumor-formation-by-enhancing-akt-activity-and-pd-l1-expression/367602/",4,{"url":32,"name":10,"@type":35,"image":36,"author":41,"headline":10,"publisher":44,"fileFormat":47,"inLanguage":8,"description":12,"dateModified":48,"datePublished":49,"encodingFormat":47,"isAccessibleForFree":50,"interactionStatistic":51},"DigitalDocument",{"url":37,"@type":38,"width":39,"height":40},"https://docshare.wps.com/thumbnails/loss-of-lats1-and-lats2-promotes-ovarian-tumor-formation-by-enhancing-akt-activity-and-pd-l1-expression/367602.png","ImageObject",300,407,{"name":42,"@type":43},"Rizky","Person",{"url":19,"name":45,"@type":46},"DocShare","Organization","application/pdf","2026-11-03","2026-09-23",true,{"@type":52,"interactionType":53,"userInteractionCount":55},"InteractionCounter",{"@type":54},"ViewAction",10,{"@type":57,"mainEntity":58},"FAQPage",[59,65,69],{"name":60,"@type":61,"acceptedAnswer":62},"What does the study show about LATS1 and LATS2 in ovarian cancer?","Question",{"text":63,"@type":64},"Inactivation of LATS1/2 is sufficient to transform normal ovarian epithelium into tumorigenic cells with increased proliferation, invasion, stemness, and EMT characteristics.","Answer",{"name":66,"@type":61,"acceptedAnswer":67},"How is PD-L1 affected by loss of LATS1/2?",{"text":68,"@type":64},"Knockout of Lats1/2 in epithelial cells increases PD-L1 expression, indicating a role for LATS1/2 in regulating immune responses and immune evasion.",{"name":70,"@type":61,"acceptedAnswer":71},"What downstream pathway activity increases after LATS1/2 loss, and how is it targeted?",{"text":72,"@type":64},"PI3K-AKT activity increases after Lats1/2 loss. The study reports partial reversal of enhanced proliferation with the AKT inhibitor MK2206, and reduced tumor progression with the YAP/TAZ inhibitor verteporfin.","https://schema.org",{"og:url":32,"og:type":75,"og:title":10,"og:site_name":45,"og:description":12},"article",{"robots":77,"canonical":32},"index,follow",{"doc_id":79,"site_id":7},367602,1790196819,{"code":4,"msg":82,"data":83},"success",[84,88,92,96,101,106,111,115,120,123,126],{"id":22,"doc_module":4,"doc_module_name":25,"category_name":85,"show_sort_weight":86,"slug":87},"Story & Novel",90,"story-novel",{"id":26,"doc_module":4,"doc_module_name":25,"category_name":89,"show_sort_weight":90,"slug":91},"Literature",80,"literature",{"id":33,"doc_module":4,"doc_module_name":25,"category_name":93,"show_sort_weight":94,"slug":95},"Exam",70,"exam",{"id":97,"doc_module":4,"doc_module_name":25,"category_name":98,"show_sort_weight":99,"slug":100},5,"Comic",60,"comic",{"id":102,"doc_module":4,"doc_module_name":25,"category_name":103,"show_sort_weight":104,"slug":105},6,"Technology",50,"technology",{"id":107,"doc_module":4,"doc_module_name":25,"category_name":108,"show_sort_weight":109,"slug":110},7,"Healthcare",40,"healthcare",{"id":112,"doc_module":4,"doc_module_name":25,"category_name":29,"show_sort_weight":113,"slug":114},8,30,"research-report",{"id":116,"doc_module":4,"doc_module_name":25,"category_name":117,"show_sort_weight":118,"slug":119},9,"Religion & Spirituality",20,"religion-spirituality",{"id":118,"doc_module":4,"doc_module_name":25,"category_name":121,"show_sort_weight":118,"slug":122},"World Cup","world-cup",{"id":55,"doc_module":4,"doc_module_name":25,"category_name":124,"show_sort_weight":55,"slug":125},"Lifestyle","lifestyle",{"id":127,"doc_module":4,"doc_module_name":25,"category_name":128,"show_sort_weight":97,"slug":129},19,"General","general",{"code":4,"msg":82,"data":131},{"doc_id":79,"user_id":132,"nickname":42,"user_avatar":133,"doc_module":4,"category_id":112,"category_name":29,"doc_title":10,"doc_description":12,"doc_content":134,"file_id":135,"file_url":136,"file_type":137,"file_size":138,"view_count":55,"is_deleted":4,"is_public":22,"is_downloadable":22,"audit_status":22,"page_count":139,"language":140,"language_code":8,"site_id":7,"html_lang":8,"table_of_contents":141,"faqs":142,"seo_title":143,"seo_description":12,"update_tm":144,"read_time":145,"preview_page_count":33,"preview_urls":146},962085564807,"https://ap-avatar.wpscdn.com/davatar_6f874abed73319feea01a86fa6f0fab8","[www.nature.com/onc](www.nature.com/onc Oncogene)[ Oncogene](www.nature.com/onc Oncogene)  \nARTICLE OPEN   \nLoss of LATS1 and LATS2 promotes ovarian tumor formation by enhancing AKT activity and PD-L1 expression  \nYalun Janie  \nZhu 1,2,4, Atefeh Abedini 1,2,4, Galaxia M. Rodriguez 1,2, Curtis W. McCloskey1,2, John Abou-Hamad 1,2, Omar Salah Salah1,2, Larocque 1,2, Mayra F. Tsoi3, Derek Boerboom3, David Cook1,2 and Barbara Vanderhyden 1,2 ✉  \n© The Author(s) 2025  \n\n| | High-grade serous ovarian cancer (HGSOC) is the deadliest and most common subtype of ovarian cancer. Unfortunately, most patients develop recurrence and, ultimately, resistance to standard platinum chemotherapy. Large tumor suppressors LATS1 and LATS2, the core Hippo signaling kinases, have been implicated in various cancer types, including ovarian cancer. The mechanism by which LATS1/2 suppresses ovarian cancer progression is currently elusive, but the expression of LATS1/2 is frequently reduced or lost in these cancers. In this study, we demonstrate that the inactivation of LATS1/2 is sufﬁcient to transform normal mouse ovarian epithelium into tumorigenic cells associated with increased cell proliferation, invasion, and stemness and epithelial–mesenchymal transition (EMT) characteristics. The knockout of Lats1/2 in the epithelial cells also leads to higher expression levels of the immune checkpoint molecule PD-L1, suggesting a regulatory role of LATS1/2 in modulating immune responses and immune evasion. In addition to the loss of LATS1/2 activating the downstream transcriptional coactivators YAP and TAZ, PI3K-AKT activity was also increased, likely contributing to enhanced tumor proliferation and survival. The stimulatory effect of Lats1/2 knockout on cell proliferation can be partially reversed by treatment with the AKT inhibitor MK2206. Treatment with verteporﬁn, a potent inhibitor of YAP/TAZ, decreases ovarian tumor progression and reduces the activated AKT in the tumors. In summary, this study uncovers several biological mechanisms for the initiation of HGSOC and identiﬁes LATS1/2 as potential prognostic indicators and therapeutic | |\n| --- | --- | --- |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  |  |  |\n|  | targets. |  |\n|  |  |  |\n|  |  |  |\n|  | Oncogene (2025) 44:2240–2252; [https://doi.org/10.1038/s41388-025-03387-z](https://doi.org/10.1038/s41388-025-03387-z) |  |\n|  |  |  |\n\nINTRODUCTION  \nEpithelial ovarian cancer is the ﬁfth most frequently occurring malignant tumor among North American women and the most lethal gynecologic cancer worldwide [1] . High-grade serous ovarian cancer (HGSOC) is the most common subtype of ovarian cancer and the deadliest, accounting for approximately 70% of ovarian cancers and having a 5-year survival rate of 45%[2] . Due to its obscure symptoms and a lack of effective methods for early detection, most HGSOC patients are diagnosed at an advanced stage. Despite advances in surgical and platinum-taxane chemotherapy, most ovarian cancers develop resistance to chemotherapy, and the availability of effective treatments for ovarian cancer remains limited [3] .  \nImmune checkpoint therapies targeting programmed cell death ligand-1(PD-L1)/programmed cell death-1 (PD-1) blockade, for example, have shown striking clinical success against multiple solid malignancies such as small cell lung carcinoma and melanoma [4] . The binding of PD-L1 to its receptor PD-1 restricts excessively active anticancer immune responses by repressing cytotoxic T cell activity and stimulating regulatory T cells (Treg) activity [5] . Both tumor cells and tumor-associated macrophages (TAM) take advantage of PD-L1 activation as a principal mechanism to evade the host’s immune system [6] . Unfortunately,  \nimmune checkpoint blockade antibodies exhibit only minimal efﬁcacy in HGSOC, with an objective response rate of only 5-20%, which is likely due to the strong immu","cbCair6BnIPHj6os","https://ap.wps.com/l/cbCair6BnIPHj6os","pdf",4281453,13,"English","# Abstract / Summary\n## Core finding: LATS1/2 loss drives tumorigenesis\n## PD-L1 and immune evasion\n## AKT activation and therapeutic modulation\n# Introduction\n## Epidemiology and treatment resistance in HGSOC\n## PD-L1/PD-1 immune checkpoint therapy limitations\n## Hippo pathway background and YAP/TAZ regulation","[{\"question\":\"What does the study show about LATS1 and LATS2 in ovarian cancer?\",\"answer\":\"Inactivation of LATS1/2 is sufficient to transform normal ovarian epithelium into tumorigenic cells with increased proliferation, invasion, stemness, and EMT characteristics.\"},{\"question\":\"How is PD-L1 affected by loss of LATS1/2?\",\"answer\":\"Knockout of Lats1/2 in epithelial cells increases PD-L1 expression, indicating a role for LATS1/2 in regulating immune responses and immune evasion.\"},{\"question\":\"What downstream pathway activity increases after LATS1/2 loss, and how is it targeted?\",\"answer\":\"PI3K-AKT activity increases after Lats1/2 loss. The study reports partial reversal of enhanced proliferation with the AKT inhibitor MK2206, and reduced tumor progression with the YAP/TAZ inhibitor verteporfin.\"}]","Loss of LATS1 and LATS2 promotes ovarian tumor formation by enhancing AKT activity and PD-L1 expression | PDF",1790171591,33,[147,151,155,159],{"page_no":22,"url":148,"width":149,"height":150},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/9b0309a96723aedac9535a4c5ec20c7e.webp",983,1305,{"page_no":26,"url":152,"width":153,"height":154},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/ab1bab7184823a8185ffcf03562b9ec3.webp",982,1304,{"page_no":30,"url":156,"width":157,"height":158},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/d7a2358ae23646125a10f41ebfc9ae41.webp",981,1303,{"page_no":33,"url":160,"width":161,"height":162},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/8944785e49686a9345399cb99c7d6e7c.webp",980,1301]